AngioDynamics ANGO
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
AngioDynamics (ANGO) Business Model and Operations Summary
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
Key Insights
AngioDynamics (ANGO) Core Market Data and Business Metrics
Latest Closing Price
$9.39Market Cap
$389.89 MillionAverage Daily Trade Volume
692,540 SharesPrice-Earnings Ratio
-1.69Total Outstanding Shares
40.63 Million SharesCEO
Mr. James C. ClemmerTotal Employees
748Dividend
No dividendIPO Date
May 27, 2004SIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
NASDAQHeadquarters
14 Plaza Drive, Latham, NY, 12110
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
December 1, 2023 to November 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-23.30 Million |
| Net Cash Flow From Financing Activities, Continuing | $-5.94 Million |
| Net Cash Flow From Financing Activities | $-5.94 Million |
| Exchange Gains/Losses | $-266,000 |
| Net Cash Flow | $-6.81 Million |
| Net Cash Flow From Operating Activities, Continuing | $-23.30 Million |
Income Statement
December 1, 2023 to November 30, 2024
| Metric | Value |
|---|---|
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Income/Loss From Continuing Operations Before Tax | $-237.39 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-224.72 Million |
| Depreciation and Amortization | $27.99 Million |
| Operating Expenses | $396.20 Million |
| Net Income/Loss Attributable To Parent | $-224.72 Million |
Comprehensive Income
December 1, 2023 to November 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $148.32 Million |
| Comprehensive Income/Loss | $-223.76 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-223.76 Million |
Balance Sheet
December 1, 2023 to November 30, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $291.55 Million |
| Inventory | $65.92 Million |
| Equity Attributable To Parent | $186.77 Million |
| Fixed Assets | $32.98 Million |
| Assets | $291.55 Million |
| Other Current Assets | $109.44 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||